TABLE 2.
Summary of 21 articles extracted by string 1 and string 2
| Article | Hair loss type | Summary of reports |
|---|---|---|
| 1. Lopez‐Leon S, et al. Res Sq. 2021 Mar 1; doi:10.1101/2021.01.27.21250617. 1 | Hair loss (type not mentioned) | As per the systematic review and meta‐analysis, 80% of patients developed one or more long‐term symptoms. Hair loss occurred in 25%. Alopecia occurred in 178 of 658 patients |
| 2. Cheng D, et al. BMJ Open Respir Res. 2021;8(1). 2 | Hair loss (type not mentioned) | In the cohort analyses of 1946 patients with COVID‐19, ongoing symptoms, including hair loss, were reported in 70% of survivors |
| 3. Xiong Q, et al. Clin Microbiol Infect. 2021 Jan;27(1):89–95. 3 | Alopecia (type not mentioned) | A telephonic survey of 538 COVID‐19 survivors identified sequelae, including alopecia (n = 154, 28.6%) 3 months after discharge from hospital |
| 4. Rinaldi F, et al. Dermatol Ther (Heidelb). 2021;11(2):339–45. 4 | AA | A questionnaire‐based survey of 392 subjects indicated that 44% of subjects relapsed with AA after about 2 months from COVID‐19 infection |
| 5. Kutlu Ö, Metin A. Dermatol Ther. 2020;33(6).e14096. 5 | AA, TE | Dermatology outpatient visits reduced from 2442 in 2019 to 738 in 2020 due to COVID‐19. Meanwhile, the proportion of AA patients increased from 1.02% to 2.71% (p = 0.001) and that of TE patients from 0.40% to 2.17% (p = 0.001) |
| 6. Turan Ç, et al. Dermatol Ther. 2020;33(4). 6 | AA | Evaluation of the diagnostic spectrum in dermatology outpatients indicated that the proportion of patients with AA increased from 1.4% to 2.7% because of COVID‐19 (p = 0.017) |
| 7. Turkmen D, et al. Dermatol Ther. 2020;33(6). 7 | TE, AA | As per the result of an online questionnaire for individuals who had to stay at home for a long time, TE was seen in 27.9% and AA on the scalp was seen in 2.8% of 563 patients |
| 8. Starace M, et al. JAAD Int. 2021;5:11–8. 8 | TE, trichodynia | All 39 patients experienced excessive hair loss within 2–3 months after COVID‐19 disease. Telogen effluvium was observed in 66.3% of patients. The pull tests for telogen effluvium assessment were strongly positive. Fifteen (38.5%) and 24 (61.5%) patients were respectively with mild and moderate COVID‐19 and did not require hospitalization |
| 9. Rossi A, et al. Skin Appendage Disord. 2021;21(5):1–5. 9 | TE | As a result of 14 patients' evaluation, TE occurred about 2 months (range, 1–3 months) after SARS‐CoV‐2 infection. The median duration of hair loss was 5 months (range, 1–6 months) |
| 10. Sharquie KE, Jabbar RI. Ir J Med Sci. 2021; doi: 10.1007/s11845‐021‐02754‐5. 10 | TE | All 39 patients experienced excessive hair loss within 2–3 months after COVID‐19 disease. The pull tests for TE assessment were strongly positive |
| 11. Rizzetto G, et al. Dermatol Ther. 2021;34(1). 11 | TE, AE (identical to the case reported in Ref. 13) | A case report of three TE cases occurring after SARS‐CoV‐2 infection. A case report of one AE case (identical to case in Ref. 13) during severe SARS‐CoV‐2 infection was also mentioned |
| 12. FIvenson D. Int J Dermatol. 2021;60(1):127. 12 | AA | Three cases of rapidly progressive AA has been noted in relationship to COVID‐19 possibly due to stress of, quarantine, and/or fear of infection |
| 13. Tanacan E, et al. Dermatol Ther. 2020;33(6). 14 | Scarring alopecia | The rate of cicatricial hair loss in the pandemic period was significantly higher compared to that in non‐pandemic period (p = 0.009) |
| 14. Turkmen D, et al. Int J Clin Pract. 2021;75(4). 15 | AGA | A comparison of 519 men in the non‐pandemic period and 568 men in the pandemic period was conducted; the number of cases of AGA in the pandemic period was low (p = 0.0174) |
| 15. Salazar Arenas MÁ, et al. Infez Med. 2021;29(1):37–45. 16 | AGA | A cross‐sectional study of 98 male patients diagnosed with COVID‐19 was performed; 45.9% had AGA |
| 16. Almeida G, et al. J Drugs Dermatol. 2021;20(1):76–83. 18 | Probable TE? | Forty‐five patients were included in a retrospective chart review, which identified seven major types of cutaneous manifestations. One of them is hair loss (probably TE) |
| 17. Aşkın Ö, et al. Dermatol Ther. 2021;34(2).19 | Other (continued AA treatment) | If the benefits outweigh the risks, patients are recommended to continue tofacitinib therapy for AA during the COVID‐19 pandemic |
| 18. Cadegiani FA, et al. Cureus. 2021;13(2). 20 | Other (COVID‐19 treatment) | The addition of an early antiandrogen therapy with dutasteride commonly used for the treatment of AGA can effectively reduce SARS‐CoV‐2 infection in combination with nitazoxanide and azithromycin |
| 19. Gupta AK, et al. J Cosmet Dermatol. 2021;20(3):929–36. 21 | Miscellaneous (Google trend search) | A survey of global trends in Google searches for hair loss products (2004–2020) revealed that the most searched term was minoxidil |
| 20. Kutlu Ö. Dermatol Ther. 2020;33(6). 22 | Miscellaneous (Google trend search) | As per Google trends, during the COVID‐19 pandemic, the interest in dermatologic terms such as “acne,” “eczema,” and “hair loss” in Turkey and Italy |
| 21. Olds H et al. Dermatol Ther. 2021;e14761. 26 | TE | Ten of 522 patients diagnosed with COVID‐19 were diagnosed to have TE caused by COVID‐19 |
Abbreviations: AA, alopecia areata; AE, anagen effluvium; AGA, androgenetic alopecia; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; TE, telogen effluvium.